|Day Low/High||30.58 / 35.77|
|52 Wk Low/High||27.65 / 300.00|
Tilray, Inc. (NASDAQ:TLRY), a global leader in cannabis research and production, today announced its support of two new clinical studies: a pilot study led by Murdoch Children's Research Institute (MCRI) in Melbourne, to evaluate the feasibility and...
Natura Naturals Inc. ("Natura"), a wholly-owned subsidiary of Tilray, Inc.
The National Association of Corporate Directors (NACD) announced the 2019 NACD Directorship 100, a list of the most influential leaders in the boardroom and corporate governance community.
A huge week is coming up for these well-known stocks.
Overwhelmed by the cannabis earnings reports? Here's the metric that Jim Cramer watches.
Plus, why investors should care about the yield curve, and a closer look at Tilray's quarter.
Stocks ended mixed Tuesday on reports that China may be pushing back against American trade talk demands.
Tilray shares turn following the company's fourth-quarter results while other pot stocks trade mixed.
It might not be time to panic yet about Tilray, but there's likely a problem ahead.
Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.
Tilray's wide trading range on Tuesday is relatively calm considering the important levels it's teetering on.
Tilray turns lower after the Canadian cannabis group posts a wider-than-expected fourth-quarter loss but says sales nearly tripled in a growing global market for medical marijuana.
Jim Cramer says that Tilray's earnings call disappointed him. Here's why he wasn't blown away.
A key aspect of the international expansion is the company's recent acquisition of hemp-food producer Manitoba Harvest in February.
Apparently, this game is all about growth right now. It certainly is not about margins.
Bristol-Myers, Tilray, and Elon Musk are some of the top headlines in business news Tuesday. Here's what Jim Cramer's watching.
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
Here's what you need to know about Tilray's earnings, Elon Musk's fight with the SEC and Bristol-Myers fight with Starboard over Celgene. Jim Cramer talks the markets
Let's check out the charts and indicators for this so-called pot play.
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
U.S. stock futures rise modestly ahead of the start of the two-day Federal Reserve meeting; the SEC blasts Tesla CEO Elon Musk for his alleged failure to abide by an agreement to curb his 'reckless' tweets; cannabis company Tilray beats revenue estimates.
Tilray shares rose in after-hours action on strong revenue as traders shrugged off a wider-than-expected loss.
Tilray, Inc., ("Tilray" or the "Company") (Nasdaq: TLRY) a global leader in cannabis research, cultivation, production and distribution, today reported financial results for the fourth quarter and year ended December 31, 2018.
Tilray is expected to increase its revenue by more than 50% from the previous quarter.
When it comes to products related to cannabis consumption, a rich universe of options continues to scale up around oils and edibles.
U.S. stock futures are mixed on Monday; the Federal Reserve is unlikely to lift interest rates when it meets this week; a meeting between Donald Trump and Chinese President Xi Jinping may be pushed off until June, a report says.
This quarter is a heavy test for Tilray because of the stock's lofty valuation.
Tilray is scheduled to report fourth-quarter results after the closing bell Monday.
Assessing Aurora and its peers, strictly on the numbers.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.